Search Within

Principal Biostatisticians

  1. "Paul Hamlin"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (11)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Epidemiology and Biostatistics (25)
  4. Hematologic Malignancies, Division of (25)
  5. Lymphoma (25)
  6. Hematology-Oncology Fellows (23)

More Groups

People
  1. Esther Drill (25)
  2. Paul Hamlin (25)
  3. Andrew Zelenetz (24)
  4. Anita Kumar (23)
  5. Ariela Noy (22)
  6. Alison Moskowitz (20)

More People

Years
  1. 2025 (5)
  2. 2024 (4)
  3. 2023 (3)
  4. 2022 (4)
  5. 2021 (3)
  6. 2020 (1)

More Years

Publications
  1. Blood (11)
  2. Haematologica (4)
  3. Journal of Clinical Oncology (3)
  4. Blood Advances (2)
  5. Leukemia and Lymphoma (2)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (13)
  2. Ferrata Storti Foundation (4)
  3. American Society of Clinical Oncology (3)
  4. Taylor & Francis Group (2)
  5. John Wiley & Sons (1)
  6. Nature Publishing Group (1)

More Publishers

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
    Correspondence

    Cassanello, G.; Drill, E.; Qiu, A.; Ewalt, M. D.; Hamlin, P.; Horwitz, S. M.; Joffe, E.; Kumar, A.; Moskowitz, A. J.; Noy, A.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: Insights from a retrospective analysis
    Journal Article

    Luttwak, E.; Robin, E. T.; Drill, E.; Boardman, A.; Caron, P.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma
    Research Letter

    Uppal, M.; Joseph, A.; Drill, E.; Hamlin, P.; Falchi, L.; Noy, A.; Owens, C.; Epstein-Peterson, Z. D.; Salles, G.; Zelenetz, A. D.; more...
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: Real-life experience
    Journal Article

    Cassanello, G.; Drill, E.; Rivas-Delgado, A.; Okwali, M.; Isgor, I.; Caron, P. C.; Epstein-Peterson, Z.; Ghione, P.; Hamlin, P. A.; Lue, J. K.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Brentuximab vedotin-based regimens for older patients with newly diagnosed classical Hodgkin lymphoma - International, multi-center real-world experience
    Meeting Abstract

    Luttwak, E.; Kambhampati, S.; Drill, E.; Ganesan, N.; Hofstetter, L.; Gurion, R.; Aumann, S.; Haran, A.; Geva, M.; Panossian, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save